CA2702243C - Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents - Google Patents

Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents Download PDF

Info

Publication number
CA2702243C
CA2702243C CA2702243A CA2702243A CA2702243C CA 2702243 C CA2702243 C CA 2702243C CA 2702243 A CA2702243 A CA 2702243A CA 2702243 A CA2702243 A CA 2702243A CA 2702243 C CA2702243 C CA 2702243C
Authority
CA
Canada
Prior art keywords
dantrolene sodium
drugs
lyophilized
solution
dantrolene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2702243A
Other languages
English (en)
French (fr)
Other versions
CA2702243A1 (en
Inventor
Ahmad Malkawi
Abeer M. Al-Ghananeem
Patrick Deluca
George A. Digenis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US WORLDMEDS LLC
Original Assignee
US WORLDMEDS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US WORLDMEDS LLC filed Critical US WORLDMEDS LLC
Publication of CA2702243A1 publication Critical patent/CA2702243A1/en
Application granted granted Critical
Publication of CA2702243C publication Critical patent/CA2702243C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2702243A 2007-10-09 2008-09-05 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents Active CA2702243C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97862607P 2007-10-09 2007-10-09
US60/978,626 2007-10-09
PCT/US2008/075406 WO2009048698A1 (en) 2007-10-09 2008-09-05 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents

Publications (2)

Publication Number Publication Date
CA2702243A1 CA2702243A1 (en) 2009-04-16
CA2702243C true CA2702243C (en) 2016-06-21

Family

ID=40316940

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2702243A Active CA2702243C (en) 2007-10-09 2008-09-05 Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents

Country Status (6)

Country Link
US (1) US8975284B2 (enExample)
EP (2) EP2583670A1 (enExample)
JP (1) JP5406197B2 (enExample)
CA (1) CA2702243C (enExample)
ES (1) ES2583804T3 (enExample)
WO (1) WO2009048698A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090061033A (ko) * 2006-10-03 2009-06-15 와이어쓰 동결건조 방법 및 장치
WO2009067175A2 (en) 2007-11-16 2009-05-28 Nektar Therapeutics Al, Corporation Oligomer-dantrolene conjugates and related compounds
US20120040970A1 (en) * 2009-04-27 2012-02-16 Al-Ghananeem Abeer M Intranasal delivery system for dantrolene
US20140072525A1 (en) * 2012-09-07 2014-03-13 Gaab, Llc Antimicrobial preparation and methods for making and using the same
US9102645B2 (en) 2013-03-15 2015-08-11 Rosalind Franklin University Of Medicine And Science Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
WO2015157212A1 (en) * 2014-04-10 2015-10-15 Us Worldmeds, Llc Stable apomorphine composition and uses thereof
US11844782B2 (en) 2015-10-20 2023-12-19 Spepharm Ag Aqueous composition comprising dantrolene
EP3641740A4 (en) * 2017-06-20 2021-03-17 Tarveda Therapeutics, Inc. TARGETED THERAPEUTICS
US11352347B2 (en) * 2017-10-20 2022-06-07 Eagle Research Labs Limited Dantrolene prodrugs and methods of their use
WO2019175761A1 (en) * 2018-03-12 2019-09-19 Orbicular Pharmaceutical Technologies Private Limited Ready to use dantrolene compositions
US20210169871A1 (en) * 2018-04-05 2021-06-10 Tarveda Therapeutics, Inc. Pharmaceutical compositions with reduced tert-butanol levels
WO2020049670A1 (ja) * 2018-09-06 2020-03-12 シミックホールディングス株式会社 ダントロレン水性製剤及びその調製方法
KR20210096152A (ko) * 2018-11-27 2021-08-04 이글 리서치 랩스 리미티드 방사선 노출을 치료하기 위한 단트롤렌 및 단트롤렌 전구약물의 용도
WO2022169582A1 (en) * 2021-02-05 2022-08-11 Uswm, Llc Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415821A (en) 1965-09-07 1968-12-10 Norwich Pharma Co 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones
US4543359A (en) 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
US5158867A (en) 1987-08-21 1992-10-27 Cryolife Inc. Method for cryopreserving blood vessels
US5145769A (en) 1987-08-21 1992-09-08 Cryolife Inc. Method for cryopreserving blood vessels
US5149621A (en) 1987-08-21 1992-09-22 Cryolife, Inc. & Medical Univ. Of South Carolina Kit for cryopreserving blood vessels
JPH01128923A (ja) * 1987-11-11 1989-05-22 Mikasa Seiyaku Kk 骨格筋弛緩外用剤
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
AU5015193A (en) * 1992-09-09 1994-03-29 Washington University Prevention or treatment of sepsis with dantrolene or azumolene
JPH06263636A (ja) * 1993-03-12 1994-09-20 Kiyoshi Kataoka 脳または高次神経疾患治療剤
JP3483148B2 (ja) * 1994-04-21 2004-01-06 久光製薬株式会社 経皮投与基剤組成物およびその薬剤組成物
US5597809A (en) 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US7758890B2 (en) * 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
EP1435781A4 (en) * 2001-06-23 2007-06-20 Lyotropic Therapeutics Llc SOLVENT SYSTEM
WO2005013919A2 (en) * 2003-03-04 2005-02-17 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina

Also Published As

Publication number Publication date
WO2009048698A9 (en) 2009-11-19
WO2009048698A4 (en) 2013-05-30
US20110015243A2 (en) 2011-01-20
JP5406197B2 (ja) 2014-02-05
CA2702243A1 (en) 2009-04-16
EP2583670A1 (en) 2013-04-24
WO2009048698A1 (en) 2009-04-16
US8975284B2 (en) 2015-03-10
JP2011500570A (ja) 2011-01-06
US20090093531A1 (en) 2009-04-09
EP2219605B1 (en) 2015-08-19
EP2219605A1 (en) 2010-08-25
ES2583804T3 (es) 2016-09-22

Similar Documents

Publication Publication Date Title
EP2219605B1 (en) Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
US20110160261A2 (en) Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
US20110042247A1 (en) Formulations of azacitidine and its derivatives
JP6869941B2 (ja) ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法
EP0833640B1 (en) Pharmaceutical composition containing lamotrigine
KR20090087079A (ko) 벤조디아제핀 구조의 ｒｓｖ 억제제를 포함하는 안정한 비경구 제형
JP2025142200A (ja) ダプトマイシン製剤
KR20190086662A (ko) 카르글룸산을 함유하는 약제학적 비경구 제형
JPH10500975A (ja) 乾燥剤を含有する注射用製剤
JP2002508330A (ja) ダルホプリスチンおよびキヌプリスチンに基づく医薬組成物ならびに調製
WO2022169582A1 (en) Compositions and methods for clear concentrated parenteral delivery of dantrolene therapeutic agents
CN111789818B (zh) 注射用盐酸罂粟碱药物组合物及制备方法
WO2021208910A1 (zh) 用于治疗病毒感染的聚合物制剂及制备方法和用途
KR20260062992A (ko) 개선된 동결건조 제형
WO2021028842A1 (en) A stable ready-to-use injectable composition of gemcitabine or its salt and methods for producing same
US20060153920A1 (en) Lyophilized pharmaceutical compositions
JP7720391B2 (ja) フォスフェニトインナトリウム固体組成物、凍結乾燥法、及びその使用
WO2019106586A1 (en) A stable glucagon formulation for emergency treatment of hypoglycemia
WO2023209731A1 (en) Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
WO2023214433A1 (en) Stable parenteral compositions of parecoxib
CN113491668A (zh) 注射用药物组合制剂及其制备方法与应用
WO2017093912A1 (en) Formulations for intravenous injection of danirixin
WO2005123137A2 (en) Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130726

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250305